Cargando…

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roex, Gils, Feys, Tom, Beguin, Yves, Kerre, Tessa, Poiré, Xavier, Lewalle, Philippe, Vandenberghe, Peter, Bron, Dominique, Anguille, Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076393/ https://www.ncbi.nlm.nih.gov/pubmed/32102267 http://dx.doi.org/10.3390/pharmaceutics12020194

Ejemplares similares

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society
por: Baron, Frédéric, et al.
Publicado: (2015)

One-step CRISPR-Cas9-mediated knockout of native TCRαβ genes in human T cells using RNA electroporation
por: Flumens, Donovan, et al.
Publicado: (2023)

Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis
por: Servais, Sophie, et al.
Publicado: (2023)

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
por: Roex, Gils, et al.
Publicado: (2022)

Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study
por: Servais, Sophie, et al.
Publicado: (2018)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials
por: Ormhøj, Maria, et al.
Publicado: (2022)

The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy
por: Campillo-Davo, Diana, et al.
Publicado: (2021)

How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation
por: Vandenhove, Benoît, et al.
Publicado: (2020)

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
por: Van Acker, Heleen H., et al.
Publicado: (2019)

Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
por: Campillo-Davo, Diana, et al.
Publicado: (2020)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019)

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022)

Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies
por: Yan, Weiqi, et al.
Publicado: (2020)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

Adherence to Sars-CoV2 vaccination in hematological patients
por: Narinx, Justine, et al.
Publicado: (2022)

Chimeric antigen receptor T‑cell therapy—a hematological success story
por: Wohlfarth, Philipp, et al.
Publicado: (2018)

Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies
por: Shen, Chunyi, et al.
Publicado: (2020)

Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
por: Yang, Zhihuan, et al.
Publicado: (2023)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

Can immunotherapy specifically target acute myeloid leukemic stem cells?
por: Snauwaert, Sylvia, et al.
Publicado: (2013)

The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial
por: Schoemans, Helene M., et al.
Publicado: (2018)

Updates on the Pivotal Roles of Mitochondria in Urothelial Carcinoma
por: Huang, Chiang-Chi, et al.
Publicado: (2022)

Aging of Bone Marrow Mesenchymal Stromal Cells: Hematopoiesis Disturbances and Potential Role in the Development of Hematologic Cancers
por: Massaro, Fulvio, et al.
Publicado: (2020)

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies
por: Levrat, Emmanuel, et al.
Publicado: (2015)

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience
por: Sun, Wei, et al.
Publicado: (2023)

Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies
por: Al Hadidi, Samer, et al.
Publicado: (2021)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells
por: Willemen, Yannick, et al.
Publicado: (2016)

B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
por: van de Donk, NWCJ, et al.
Publicado: (2022)

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
por: Heine, Renaud, et al.
Publicado: (2021)

Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy
por: Xue, Lei, et al.
Publicado: (2021)

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2023)

In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update
por: Soundara Rajan, Thangavelu, et al.
Publicado: (2020)

Apoptotic and Non-Apoptotic Modalities of Thymoquinone-Induced Lymphoma Cell Death: Highlight of the Role of Cytosolic Calcium and Necroptosis
por: Berehab, Mimoune, et al.
Publicado: (2021)

Updates on the hematologic tumor microenvironment and its therapeutic targeting
por: Forte, Dorian, et al.
Publicado: (2019)

Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies
por: Xie, Bailu, et al.
Publicado: (2022)

Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review
por: Hanna, Kerollos S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gr4452km75s4spbbirbf85enjl